- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07772167
Identifying Multidimensional Signatures of Gastric Interoception in Functional Dyspepsia (IMAGINE)
14 augusti 2026 uppdaterad av: Helen Burton-Murray, PHD, Massachusetts General Hospital
This study is being conducted to investigate gut-brain communication in individuals with functional dyspepsia and anorexia nervosa.
The hope is that what the investigators learn from this study will improve the understanding the conditions better to improve treatments.
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
150
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Caroline Adams
- Telefonnummer: 617-643-7884
- E-post: imaginestudy@mgb.org
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts General Hospital
-
Kontakt:
- IMAGINE Study Coordinator CRC
- Telefonnummer: 617-643-7884
- E-post: imaginestudy@mgb.org
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Beskrivning
Participant Inclusion Criteria--
Functional Dyspepsia Group:
- Males and females; ages 18-65 years
- Rome V functional dyspepsia post-prandial distress syndrome subtype
- Negative upper endoscopy or upper GI series to rule out structural/organic cause for FD
- greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
- Fluent in English
- Willing and able to provide informed consent
- Stable dose for 30 days prior to Visit 1 if on a neuropsychiatric medication (e.g., TCA, SNRI, SSRI mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)
- No current plans to initiate a new or change dosing on a neuropsychiatric medication within the study period
Anorexia Nervosa Group:
- Males and females; ages 18-65 years
- DSM-5 anorexia restricting-type by the Eating Disorder Module in the Diagnostic Interview for Mood, Anxiety, and OCD and related Neuropsychiatric Disorders (DIAMOND)
- greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
- Fluent in English
- Willing and able to provide informed consent
- Stable dose for 30 days prior to Visit 1 if on an SSRI
- No current plans to initiate a new neuromodulator
- No current plans to initiate a new SSRI or change dosing on an SSRI
Healthy Controls:
- Males and females; ages 18-65 years
- BMI greater than or equal to 18.5 kg/m2
- Fluent in English
- Willing and able to provide informed consent
Participant Exclusion Criteria--
Functional Dyspepsia Group:
Presence of other conditions that could explain the patient's symptoms by medical chart:
- Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT)
- Active H.pylori (by CLO test or stool antigen test)
- Active inflammatory bowel disease
- Eosinophilic gastroenteritis or eosinophilic esophagitis
- Acute renal failure
- Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis
- Acute liver failure
- Any acute gastrointestinal process
- Any plausible structural or metabolic causes
- Heartburn as predominant symptom
- History of peptic ulcer
- Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)
- Endorses any contraindications to MRI
- Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
- Allergy to pineapple (used in the test meal during MRI)
- History of GI tract surgery or any serious medical condition (e.g., cancer)
- Pregnancy/breastfeeding within the last 8 weeks
- Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
- Narcotic analgesics greater than three days per week
- Cannabinoid use greater than three days per week
- Intellectual disability by history
- Illiteracy
- History of weight/shape-based eating disorder including anorexia nervosa by DIAMOND
- Current binge eating by DIAMOND
- Current self-induced vomiting by DIAMOND
- Current laxative or diuretic misuse by DIAMOND
- Current substance/alcohol use disorder within past year by DIAMOND
- Current/history of psychosis by DIAMOND
- Current mania by DIAMOND
- Active suicidal ideation by modified DIAMOND abbreviated suicide module; passive suicidal ideation is allowed
- Inability or unwillingness to consume food by mouth
- Inability to provide informed consent
Anorexia Nervosa Group:
- Diagnosis of chronic gastrointestinal disorder
- Rome V functional dyspepsia
- Endorses any contraindications to MRI
- Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
- Allergy to pineapple (used in the test meal during MRI)
- History of GI tract surgery or any serious medical condition (e.g., cancer)
- Pregnancy/breastfeeding within the last 8 weeks
- Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
- Narcotic analgesics greater than three days per week
- Cannabinoid use greater than three days per week
- Intellectual disability by history
- Illiteracy
- Current binge eating by DIAMOND
- Current self-induced vomiting by DIAMOND
- Current laxative or diuretic misuse by DIAMOND
- Current substance/alcohol use disorder within past year by DIAMOND
- Current/history of psychosis by DIAMOND
- Current mania by DIAMOND
- Active suicidal ideation by DIAMOND abbreviated suicide module; passive suicidal ideation is allowed
- Inability or unwillingness to consume food by mouth
- Inability to provide informed consent
- Current use of neuropsychiatric medication other than an SSRI (e.g., TCA, SNRI, mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)
Healthy Controls:
- Diagnosis of chronic gastrointestinal or pain disorder
- Rome V functional dyspepsia
- greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
- Current use of a medication known to influence gastric sensorimotor functions (including neuromodulators and SSRIs)
- Active psychiatric disorder including a feeding/eating disorder by DIAMOND
- Endorses any contraindications to MRI
- Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
- Allergy to pineapple (used in the test meal during MRI)
- History of GI tract surgery or any serious medical condition (e.g., cancer)
- Pregnancy/breastfeeding within the last 8 weeks
- Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
- Narcotic analgesics greater than three days per week
- Cannabinoid use greater than three days per week
- Intellectual disability by history
- Illiteracy
- Current binge eating by DIAMOND
- Current self-induced vomiting by DIAMOND
- Current laxative or diuretic misuse by DIAMOND
- Current substance/alcohol use disorder within past year by DIAMOND
- Current/history of psychosis by DIAMOND
- Current mania by DIAMOND
- Active suicidal ideation by DIAMOND modified suicide module; passive suicidal ideation is allowed
- Inability or unwillingness to consume food by mouth
- Inability to provide informed consent
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Functional Dyspepsia, Healthy Control, Anorexia Nervosa
|
Pineapple pudding snack, with pre- and post-snack fMRI
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Visual interoception task
Tidsram: Day 1, visit 1, 30-minute scan and visit 2 (within approximately two weeks of day 1), 30-minute scan
|
The study team will be investigating brain activity and connectivity during an interoception task.
This will be measured via functional magnetic resonance imaging (fMRI) which is able to measure blood flow to regions of the brain.
|
Day 1, visit 1, 30-minute scan and visit 2 (within approximately two weeks of day 1), 30-minute scan
|
|
Resting state connectivity
Tidsram: Visit 2 (second visit, within approximately 2 weeks of day 1 of the study), 60 minute scan.
|
Change in brain activity during rest pre and post prandially using functional magnetic resonance imaging (fMRI).
|
Visit 2 (second visit, within approximately 2 weeks of day 1 of the study), 60 minute scan.
|
|
Gastric peristaltic velocity
Tidsram: 30 minutes (only in Visit 2, within approximately two weeks of Visit 1)
|
MRI-derived gastric motility outcome
|
30 minutes (only in Visit 2, within approximately two weeks of Visit 1)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Helen Burton-Murray, PhD, Massachusetts General Hospital
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
16 mars 2026
Primärt slutförande (Beräknad)
1 mars 2030
Avslutad studie (Beräknad)
1 mars 2031
Studieregistreringsdatum
Först inskickad
29 juni 2026
Först inskickad som uppfyllde QC-kriterierna
14 augusti 2026
Första postat (Faktisk)
19 augusti 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
19 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2025P001856
- R01DK145599 (U.S.S. NIH-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .